There is limited information regarding acute toxicity (LD50) of daxibotulinumtoxinA. The estimated human LD50 of botulinum toxins falls ranges from 1 to 3 ng/kg.L47860
Excessive doses of daxibotulinumtoxinA may produce neuromuscular weakness with a variety of symptoms. Respiratory support may be required where excessive doses cause paralysis of the respiratory muscles. In the event of an overdose, the patient should be medically monitored for symptoms of excessive muscle weakness or muscle paralysis. Symptomatic treatment may be necessary. Symptoms of overdose are not likely to be present immediately following injection. Should accidental injection or oral ingestion occur, the person should be medically supervised for several weeks for signs and symptoms of excessive muscle weakness or paralysis. The antitoxin raised against botulinum toxin may be requested through the Centers for Disease Control and Prevention (CDC) in the US; however, the antitoxin will not reverse any botulinum toxin-induced effects already apparent by the time of antitoxin administration.L47840
DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. It is a botulinum toxin without accessory proteins purified from the bacterium Clostridium botulinum type A,L47840 the gram-positive anaerobic bacterium primarily present in soil. C. botulinum is known to produce toxins that can cause botulism in humans.A261075, L47860
DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.L47865 On August 14, 2023, the drug was also approved for the treatment of cervical dystonia.L47870 DAXI or DAXXIFY, a product of daxibotulinumtoxinA, incorporates RTP004, a proprietary synthetic stabilizing peptide for enhanced product stability.A261080, A261085
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Capreomycin | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Capreomycin. |
| Botulinum toxin type B | Botulinum toxin type B may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Botulinum toxin type A | Botulinum toxin type A may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Cyclosporine | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Cyclosporine. |
| Doxycycline | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Doxycycline. |
| Lymecycline | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Lymecycline. |
| Piperacillin | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Piperacillin. |
| Framycetin | Framycetin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Clomocycline | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Clomocycline. |
| Quinine | Quinine may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Vancomycin | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Vancomycin. |
| Tigecycline | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Tigecycline. |
| Oxytetracycline | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Oxytetracycline. |
| Chloroquine | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Chloroquine. |
| Demeclocycline | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Demeclocycline. |
| Magnesium sulfate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium sulfate. |
| Mecamylamine | Mecamylamine may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Tobramycin | Tobramycin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Tetracycline | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Tetracycline. |
| Gentamicin | Gentamicin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Colistin | Colistin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Etacrynic acid | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Etacrynic acid. |
| Quinidine | Quinidine may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Metacycline | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Metacycline. |
| Netilmicin | Netilmicin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Neomycin | Neomycin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Minocycline | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Minocycline. |
| Procainamide | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Procainamide. |
| Streptomycin | Streptomycin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Colistimethate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Colistimethate. |
| Kanamycin | Kanamycin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Clindamycin | The risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with DaxibotulinumtoxinA. |
| Dantrolene | Dantrolene may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Rolitetracycline | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Rolitetracycline. |
| Magnesium oxide | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium oxide. |
| Magnesium cation | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium cation. |
| Paromomycin | Paromomycin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Lincomycin | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Lincomycin. |
| Ribostamycin | Ribostamycin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Geneticin | Geneticin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Apramycin | Apramycin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Gentamicin C1a | Gentamicin C1a may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Neamine | Neamine may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Arbekacin | Arbekacin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Viomycin | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Viomycin. |
| Puromycin | Puromycin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Magnesium hydroxide | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium hydroxide. |
| Magnesium trisilicate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium trisilicate. |
| Magnesium chloride | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium chloride. |
| Magnesium acetate tetrahydrate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium acetate tetrahydrate. |
| Magnesium carbonate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium carbonate. |
| Magnesium citrate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium citrate. |
| Magnesium glycinate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium glycinate. |
| Magnesium Aluminum Silicate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium Aluminum Silicate. |
| Dihydrostreptomycin | Dihydrostreptomycin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Hygromycin B | Hygromycin B may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Sisomicin | Sisomicin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Plazomicin | Plazomicin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Magnesium silicate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium silicate. |
| Penimepicycline | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Penimepicycline. |
| Magnesium aspartate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium aspartate. |
| Isepamicin | Isepamicin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Magnesium gluconate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium gluconate. |
| Magnesium orotate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium orotate. |
| Magnesium phosphate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium phosphate. |
| Magnesium acetate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium acetate. |
| Magnesium stearate | The therapeutic efficacy of DaxibotulinumtoxinA can be increased when used in combination with Magnesium stearate. |
| Digoxin | The risk or severity of Cardiac Arrhythmia can be increased when DaxibotulinumtoxinA is combined with Digoxin. |
| Acetyldigitoxin | The risk or severity of Cardiac Arrhythmia can be increased when DaxibotulinumtoxinA is combined with Acetyldigitoxin. |
| Deslanoside | The risk or severity of Cardiac Arrhythmia can be increased when DaxibotulinumtoxinA is combined with Deslanoside. |
| Ouabain | The risk or severity of Cardiac Arrhythmia can be increased when DaxibotulinumtoxinA is combined with Ouabain. |
| Digitoxin | The risk or severity of Cardiac Arrhythmia can be increased when DaxibotulinumtoxinA is combined with Digitoxin. |
| Oleandrin | The risk or severity of Cardiac Arrhythmia can be increased when DaxibotulinumtoxinA is combined with Oleandrin. |
| Cymarin | The risk or severity of Cardiac Arrhythmia can be increased when DaxibotulinumtoxinA is combined with Cymarin. |
| Proscillaridin | The risk or severity of Cardiac Arrhythmia can be increased when DaxibotulinumtoxinA is combined with Proscillaridin. |
| Metildigoxin | The risk or severity of Cardiac Arrhythmia can be increased when DaxibotulinumtoxinA is combined with Metildigoxin. |
| Lanatoside C | The risk or severity of Cardiac Arrhythmia can be increased when DaxibotulinumtoxinA is combined with Lanatoside C. |
| Gitoformate | The risk or severity of Cardiac Arrhythmia can be increased when DaxibotulinumtoxinA is combined with Gitoformate. |
| Acetyldigoxin | The risk or severity of Cardiac Arrhythmia can be increased when DaxibotulinumtoxinA is combined with Acetyldigoxin. |
| Peruvoside | The risk or severity of Cardiac Arrhythmia can be increased when DaxibotulinumtoxinA is combined with Peruvoside. |
| Phenytoin | The therapeutic efficacy of DaxibotulinumtoxinA can be decreased when used in combination with Phenytoin. |
| Fosphenytoin | The therapeutic efficacy of DaxibotulinumtoxinA can be decreased when used in combination with Fosphenytoin. |
| Flunisolide | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Flunisolide. |
| Fluorometholone | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Fluorometholone. |
| Beclomethasone dipropionate | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Beclomethasone dipropionate. |
| Betamethasone | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Betamethasone. |
| Desoximetasone | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Desoximetasone. |
| Fluticasone propionate | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Fluocinolone acetonide. |
| Triamcinolone | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Triamcinolone. |
| Prednisone | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Prednisone. |
| Flumethasone | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Flumethasone. |
| Fludrocortisone | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Fludrocortisone. |
| Hydrocortisone | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Hydrocortisone. |
| Mometasone | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Mometasone. |
| Prednisolone | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Prednisolone. |
| Methylprednisolone | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Methylprednisolone. |
| Clobetasol propionate | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Clobetasol propionate. |
| Fluocinonide | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Fluocinonide. |
| Trilostane | The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Trilostane. |